SI2211904T1 - CD19 vezavna sredstva in njihove uporabe - Google Patents

CD19 vezavna sredstva in njihove uporabe

Info

Publication number
SI2211904T1
SI2211904T1 SI200831686A SI200831686A SI2211904T1 SI 2211904 T1 SI2211904 T1 SI 2211904T1 SI 200831686 A SI200831686 A SI 200831686A SI 200831686 A SI200831686 A SI 200831686A SI 2211904 T1 SI2211904 T1 SI 2211904T1
Authority
SI
Slovenia
Prior art keywords
binding agents
binding
agents
Prior art date
Application number
SI200831686A
Other languages
English (en)
Slovenian (sl)
Inventor
Charlotte Mcdonagh
Charles G. Cerveny
Dennis Benjamin
Paul Carter
Hans Peter Gerber
Original Assignee
Seattle Genetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics, Inc. filed Critical Seattle Genetics, Inc.
Publication of SI2211904T1 publication Critical patent/SI2211904T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SI200831686A 2007-10-19 2008-10-17 CD19 vezavna sredstva in njihove uporabe SI2211904T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US98120607P 2007-10-19 2007-10-19
US1921408P 2008-01-04 2008-01-04
US8016908P 2008-07-11 2008-07-11
EP08840713.5A EP2211904B1 (en) 2007-10-19 2008-10-17 Cd19 binding agents and uses thereof
PCT/US2008/080373 WO2009052431A2 (en) 2007-10-19 2008-10-17 Cd19 binding agents and uses thereof

Publications (1)

Publication Number Publication Date
SI2211904T1 true SI2211904T1 (sl) 2016-12-30

Family

ID=40568090

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200831686A SI2211904T1 (sl) 2007-10-19 2008-10-17 CD19 vezavna sredstva in njihove uporabe

Country Status (20)

Country Link
US (6) US7968687B2 (US07794700-20100914-C00152.png)
EP (1) EP2211904B1 (US07794700-20100914-C00152.png)
JP (2) JP5727786B2 (US07794700-20100914-C00152.png)
KR (1) KR101658083B1 (US07794700-20100914-C00152.png)
CN (1) CN101903403B (US07794700-20100914-C00152.png)
AU (1) AU2008311815B2 (US07794700-20100914-C00152.png)
CA (1) CA2702555A1 (US07794700-20100914-C00152.png)
CY (1) CY1118349T1 (US07794700-20100914-C00152.png)
DK (1) DK2211904T3 (US07794700-20100914-C00152.png)
ES (1) ES2599172T3 (US07794700-20100914-C00152.png)
HK (1) HK1143321A1 (US07794700-20100914-C00152.png)
HR (1) HRP20161345T1 (US07794700-20100914-C00152.png)
HU (1) HUE031533T2 (US07794700-20100914-C00152.png)
LT (1) LT2211904T (US07794700-20100914-C00152.png)
MX (1) MX2010004219A (US07794700-20100914-C00152.png)
PL (1) PL2211904T3 (US07794700-20100914-C00152.png)
PT (1) PT2211904T (US07794700-20100914-C00152.png)
RU (1) RU2476441C2 (US07794700-20100914-C00152.png)
SI (1) SI2211904T1 (US07794700-20100914-C00152.png)
WO (1) WO2009052431A2 (US07794700-20100914-C00152.png)

Families Citing this family (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
ES2715776T3 (es) 2004-11-12 2019-06-06 Seattle Genetics Inc Auristatinas que tienen una unidad de ácido aminobenzoico en el extremo N
US7750116B1 (en) * 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
ES2523915T5 (es) 2006-12-01 2022-05-26 Seagen Inc Agentes de unión a la diana variantes y usos de los mismos
JP5779350B2 (ja) 2007-03-27 2015-09-16 シー レーン バイオテクノロジーズ， エルエルシー 抗体代替軽鎖配列を含む構築物およびライブラリー
WO2009012256A1 (en) 2007-07-16 2009-01-22 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
ES2381788T3 (es) 2007-07-16 2012-05-31 Genentech, Inc. Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
US7968687B2 (en) 2007-10-19 2011-06-28 Seattle Genetics, Inc. CD19 binding agents and uses thereof
IL287292B (en) 2008-01-31 2022-09-01 Genentech Inc and fusion antibody-drug-cd79b engineered antibodies cysteine-
CA2723197C (en) * 2008-05-02 2017-09-19 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
CN102482345A (zh) 2009-05-13 2012-05-30 航道生物技术有限责任公司 针对流感病毒的中和分子
US8785600B2 (en) 2009-10-23 2014-07-22 Millennium Pharmaceuticals, Inc. Anti-GCC antibody molecules and related compositions and methods
EP2533804B1 (en) 2010-02-08 2018-04-11 Agensys, Inc. Antibody drug conjugates (adc) that bind to 161p2f10b proteins
PT2542576T (pt) 2010-03-02 2016-07-14 Seattle Genetics Inc Métodos para rastreio de anticorpos
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP3513794A3 (en) 2010-08-05 2019-10-16 Seattle Genetics, Inc. Fucose analogs for inhibition of protein fucosylation in vivo
JP5884139B2 (ja) * 2010-10-04 2016-03-15 国立研究開発法人理化学研究所 Ｍｈｃクラスｉｉを発現する悪性腫瘍の治療薬
US9272052B2 (en) 2010-10-22 2016-03-01 Seattle Genetics, Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
JP5721858B2 (ja) 2010-12-23 2015-05-20 ユーリタ アクチエンゲゼルシャフトＥｕｌｉｔｈａ Ａｇ 大きな面積にわたってナノ構造を製造するためのシステムおよび方法
PL2654780T3 (pl) 2010-12-23 2017-07-31 Janssen Biotech, Inc Aktywne mutanty przeciwciała fc odporne na proteazy
MX342860B (es) * 2011-04-01 2016-10-14 Wyeth Llc Conjugados de anticuerpo-fármaco.
KR101972303B1 (ko) 2011-06-10 2019-04-25 메르사나 테라퓨틱스, 인코포레이티드 단백질-중합체-약물 접합체
CA2842860A1 (en) 2011-07-28 2013-01-31 Sea Lane Biotechnologies, Llc Sur-binding proteins
PL2744515T3 (pl) 2011-08-16 2022-05-30 Morphosys Ag Terapia skojarzona przeciwciałem anty-cd19 i iperytem azotowym
LT2744826T (lt) 2011-08-16 2022-04-25 Morphosys Ag Kombinuota terapija su anti-cd19 antikūnu ir purino analogu
CN102343083A (zh) * 2011-10-17 2012-02-08 中国科学院成都生物研究所 一种抗病毒的组合药物
WO2013067581A1 (en) * 2011-11-09 2013-05-16 Children's Cancer Institute Australia for Medical Research Cancer treatment
ES2710916T3 (es) 2011-12-22 2019-04-29 I2 Pharmaceuticals Inc Proteínas de unión sustitutas
JP2015505537A (ja) 2012-01-20 2015-02-23 シー レーン バイオテクノロジーズ， エルエルシー 結合分子コンジュゲート
EP2812702B1 (en) 2012-02-10 2019-04-17 Seattle Genetics, Inc. Diagnosis and management of CD30-expressing cancers
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
JP6423340B2 (ja) 2012-05-15 2018-11-14 シアトル ジェネティクス，インコーポレイティド 自己安定化リンカー結合体
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
WO2014004376A2 (en) 2012-06-26 2014-01-03 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
WO2014011987A1 (en) * 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Compositions and methods for regulating car t cells
ES2528892T3 (es) 2012-07-30 2015-02-13 Nbe-Therapeutics Llc Identificación mediada por trasposición de proteínas de unión o funcionales específicas
CA2882725C (en) 2012-08-23 2021-03-09 Regents Of The University Of Minnesota Treatment of sickle cell disease and inflammatory conditions
EP2888283B1 (en) 2012-08-24 2018-09-19 The Regents of The University of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
PT2839860T (pt) 2012-10-12 2019-07-29 Medimmune Ltd Pirrolobenzodiazepinas e conjugados das mesmas
NO2789793T3 (US07794700-20100914-C00152.png) * 2012-10-24 2018-01-27
IN2015DN02349A (US07794700-20100914-C00152.png) 2012-10-24 2015-08-28 Polytherics Ltd
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
EP2928503B1 (en) 2012-12-10 2019-02-20 Mersana Therapeutics, Inc. Conjugates of auristatin compounds
AU2013364043B2 (en) 2012-12-21 2018-01-04 Seagen Inc. Anti-NTB-A antibodies and related compositions and methods
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
US9840560B2 (en) * 2013-03-15 2017-12-12 Alper Biotech Llc Monoclonal antibodies to EGFR, and uses therefor
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
TWI654206B (zh) * 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
LT3546572T (lt) * 2013-05-13 2024-05-27 Cellectis Cd19 specifinis chimerinis antigeno receptorius ir jo panaudojimas
CA2921707C (en) 2013-10-15 2023-03-28 Seattle Genetics, Inc. Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
PL3082877T3 (pl) 2013-12-17 2020-02-28 Novartis Ag Cytotoksyczne peptydy i ich koniugaty
EP4190809A1 (en) 2014-02-11 2023-06-07 Seagen Inc. Selective reduction of proteins
SG10202001468UA (en) 2014-02-17 2020-04-29 Seattle Genetics Inc Hydrophilic antibody-drug conjugates
EP3725812B1 (en) 2014-03-03 2023-09-27 Academia Sinica Bi-specific antibodies and uses thereof
CA2943334A1 (en) 2014-03-19 2015-09-24 Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof
JP2017512814A (ja) * 2014-04-07 2017-05-25 シアトル ジェネティックス， インコーポレイテッド 抗ｃｄ１９抗体および抗体−薬物結合体のための安定な製剤
JP2017512801A (ja) * 2014-04-08 2017-05-25 シアトル ジェネティックス， インコーポレイテッド Ｃｄ１９抗体薬物コンジュゲートの最適な投薬
MX2016016515A (es) 2014-06-13 2017-04-27 Novartis Ag Derivados de auristatina y conjugados de los mismos.
DK3160513T3 (da) 2014-06-30 2020-04-06 Glykos Finland Oy Saccharidderivat af en toksisk payload og antistofkonjugater deraf
EP3188733B1 (en) 2014-09-03 2019-11-06 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
IL285102B2 (en) 2014-09-11 2024-06-01 Seagen Inc Targeted administration of medicinal substances containing a tertiary amine
EP3689910A3 (en) 2014-09-23 2020-12-02 F. Hoffmann-La Roche AG Method of using anti-cd79b immunoconjugates
CR20170109A (es) * 2014-09-26 2017-07-26 Macrogenics Inc Diacuerpos monovalentes biespecificos que son capaces de unir cd19 y cd3, y usos de los mismos
MA41414A (fr) * 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
EA201791819A1 (ru) * 2015-02-12 2017-12-29 Сиэтл Дженетикс, Инк. Комбинированная терапия с применением конъюгата антитела против cd19 с лекарственным средством и винкристина
SG11201706786UA (en) 2015-03-18 2017-09-28 Seattle Genetics Inc Cd48 antibodies and conjugates thereof
CN114601931B (zh) 2015-05-26 2023-09-01 莫佛塞斯公司 抗-cd19抗体和布鲁顿酪氨酸激酶抑制剂的组合及其用途
WO2015151079A2 (en) * 2015-06-20 2015-10-08 Hangzhou Dac Biotech Co, Ltd Auristatin analogues and their conjugates with cell-binding molecules
CN107735105B (zh) 2015-06-30 2022-09-16 西雅图基因公司 抗ntb-a抗体和相关组合物以及方法
RS62260B1 (sr) 2015-08-21 2021-09-30 Morphosys Ag Kombinacije i njihova upotreba
EP3347049B1 (en) 2015-09-08 2024-07-03 Waters Technologies Corporation Multidimensional chromatography method for analysis of antibody-drug conjugates
MA44909A (fr) 2015-09-15 2018-07-25 Acerta Pharma Bv Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
CA3001859A1 (en) 2015-10-16 2017-04-20 The Trustees Of Columbia University In The City Of New York Compositions and methods for inhibition of lineage specific antigens
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
AU2016363013B2 (en) 2015-12-04 2022-03-10 Seagen Inc. Conjugates of quaternized tubulysin compounds
IL260732B1 (en) 2016-02-17 2024-04-01 Seagen Inc BCMA antibodies and their use for the treatment of cancer and immune disorders
US11027021B2 (en) 2016-03-15 2021-06-08 Seagen Inc. Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors
SG11201807827VA (en) 2016-03-25 2018-10-30 Seattle Genetics Inc Process for the preparation of pegylated drug-linkers and intermediates thereof
JP7208010B2 (ja) * 2016-03-29 2023-01-18 ユニバーシティ オブ サザン カリフォルニア 癌を標的とするキメラ抗原受容体
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
HUE054860T2 (hu) 2016-05-30 2021-10-28 Morphosys Ag Eljárás betegekben CD19 elleni ellenanyagon alapuló terápia terápiás hasznosságának elõrejelzésére
KR102533875B1 (ko) 2016-06-27 2023-05-18 모르포시스 아게 항-cd19 항체 제제
US10688181B2 (en) 2016-06-27 2020-06-23 The Regents Of The University Of California Cancer treatment combinations
EP3487525A4 (en) * 2016-07-22 2020-03-18 Seattle Genetics, Inc. COMBINATION THERAPY WITH CD19-ADC AND RCHP
TW201808343A (zh) 2016-08-09 2018-03-16 美商西雅圖遺傳學公司 具有改善之生理化學性質之具自我穩定連接子之藥物結合物
US20180064758A1 (en) * 2016-09-05 2018-03-08 Ucl Business Plc Chimeric antigen receptor
US20200023072A1 (en) 2016-10-11 2020-01-23 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
BR112019006778A2 (pt) 2016-10-18 2019-10-15 Seattle Genetics Inc Composição de conjugado de aglutinante-fármaco, formulação, uso da mesma, método para preparar uma composição ou composto de conjugado de aglutinantefármaco,e, composto de ligante de fármaco
PL3532098T3 (pl) 2016-10-28 2022-01-31 Morphosys Ag Kombinacja przeciwciała anty cd19 z inhibitorem blc-2 i ich zastosowania
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
CN116672463A (zh) * 2017-02-17 2023-09-01 浙江特瑞思药业股份有限公司 靶向cd20抗体偶联药物的制备方法、抗体偶联药物及其用途
JP7337698B2 (ja) 2017-02-28 2023-09-04 シージェン インコーポレイテッド コンジュゲート化のためのシステイン突然変異抗体
MX2019010196A (es) * 2017-02-28 2019-12-19 Vor Biopharma Inc Composiciones y métodos para la inhibición de proteínas específicas del linaje.
IL269398B2 (en) 2017-03-24 2024-05-01 Seagen Inc A process for the preparation of glucuronide-drug binders and their intermediates
WO2018195339A1 (en) 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
KR20190141181A (ko) 2017-04-27 2019-12-23 시애틀 지네틱스, 인크. 사차화된 니코틴아미드 아데닌 다이뉴클레오타이드 구제 경로 억제제 콘쥬게이트
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
SG11201909715VA (en) 2017-05-31 2019-11-28 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
US11634488B2 (en) 2017-07-10 2023-04-25 International—Drug—Development—Biotech Treatment of B cell malignancies using afucosylated pro-apoptotic anti-CD19 antibodies in combination with anti CD20 antibodies or chemotherapeutics
WO2019031615A1 (ja) * 2017-08-10 2019-02-14 大日本住友製薬株式会社 ヘミアスタリン誘導体及びこれらの抗体薬物複合体
CN111032676A (zh) * 2017-08-10 2020-04-17 大日本住友制药株式会社 包含哈米特林衍生物的抗体药物复合物
CN109535253B (zh) 2017-09-21 2022-11-04 上海药明生物技术有限公司 新型抗cd19抗体
CN111201244A (zh) 2017-10-12 2020-05-26 学校法人庆应义塾 特异性结合到水通道蛋白3(aqp3)的细胞外域的抗aqp3单克隆抗体及其用途
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
AU2018375182A1 (en) 2017-12-01 2020-06-11 Seagen Inc. Humanized anti-LIV1 antibodies for the treatment of breast cancer
AR113862A1 (es) 2017-12-01 2020-06-17 Seattle Genetics Inc Anticuerpos anti-cd47 y sus usos para tratar cáncer
US11672827B2 (en) * 2017-12-23 2023-06-13 Uwell Biopharma Inc. Pharmaceutical chimeric receptor composition and method thereof
WO2019136180A2 (en) * 2018-01-04 2019-07-11 Avidity Biosciences Llc Heteroduplex nucleic acid molecules and uses thereof
EP3768714A1 (en) 2018-03-23 2021-01-27 Seagen Inc. Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
US20220111065A1 (en) 2018-05-23 2022-04-14 Adc Therapeutics Sa Molecular adjuvant
CN112512587A (zh) 2018-08-06 2021-03-16 第一三共株式会社 抗体药物缀合物和微管蛋白抑制剂的组合
CN113423725A (zh) 2018-08-28 2021-09-21 Vor生物制药股份有限公司 遗传工程化造血干细胞及其用途
CA3128368A1 (en) * 2019-02-01 2020-08-06 Memorial Sloan Kettering Cancer Center Senolytic car-t cells targeting upar, a cell surface and secreted senescence biomarker
WO2020163225A1 (en) 2019-02-05 2020-08-13 Seattle Genetics, Inc. Anti-cd228 antibodies and antibody-drug conjugates
JP7479302B2 (ja) 2019-02-13 2024-05-08 住友ファーマ株式会社 ヘミアスタリン誘導体とその抗体薬物複合体
WO2020213084A1 (en) 2019-04-17 2020-10-22 Keio University Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof
CA3137664A1 (en) 2019-05-03 2020-11-12 Morphosys Ag Anti-cd19 therapy in patients having a limited number of nk cells
CN110128551A (zh) * 2019-06-05 2019-08-16 上海科弈药业科技有限公司 一种针对cd19+肿瘤的多功能融合蛋白及其应用
TW202112801A (zh) 2019-06-05 2021-04-01 美商西雅圖遺傳學公司 純化遮蔽抗體之方法
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
TW202112354A (zh) 2019-06-05 2021-04-01 美商西雅圖遺傳學公司 遮蔽抗體調配物
MX2022000853A (es) 2019-07-22 2022-03-17 Seagen Inc Anticuerpos anti-liv1 humanizados para el tratamiento de cancer.
EP4038194A1 (en) 2019-10-04 2022-08-10 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant aav
AU2020358859A1 (en) 2019-10-04 2022-05-12 Seagen Inc. Anti-PD-L1 antibodies and antibody-drug conjugates
IL292181A (en) 2019-10-31 2022-06-01 Morphosys Ag Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
CN115151565A (zh) 2019-10-31 2022-10-04 莫佛塞斯公司 包含抗CD19抗体和γδT细胞的抗肿瘤组合疗法
CA3161283A1 (en) * 2019-12-11 2021-06-17 Cullinan Oncology, Inc. Anti-cd19 antibodies and multi-specific binding proteins
WO2021119531A1 (en) * 2019-12-11 2021-06-17 Cullinan Management, Inc. Anti-serum albumin antibodies
JP2023516344A (ja) * 2020-03-03 2023-04-19 システィミューン， インク． 抗ｃｄ１９抗体、その使用方法及び製造方法
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
US20230173093A1 (en) 2020-04-10 2023-06-08 Seagen Inc. Charge variant linkers
CA3181827A1 (en) 2020-06-22 2021-12-30 Morphosys Ag Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirp?-cd47 innate immune checkpoint
EP4192871A1 (en) 2020-08-04 2023-06-14 Seagen Inc. Anti-cd228 antibodies and antibody-drug conjugates
MX2023003404A (es) 2020-09-28 2023-03-31 Seagen Inc Anticuerpos anti-l1vi humanizados para el tratamiento del cancer.
EP4225794A1 (en) 2020-10-06 2023-08-16 Xencor, Inc. Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus erythematous (sle)
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
JP2023548538A (ja) 2020-11-08 2023-11-17 シージェン インコーポレイテッド 併用療法
KR20230131464A (ko) 2020-12-04 2023-09-13 모르포시스 아게 항-cd19 병용 요법
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
IL308296A (en) * 2021-05-07 2024-01-01 Viela Bio Inc Use of anti-CD19 antibody to treat myasthenia gravis
EP4370211A1 (en) 2021-07-14 2024-05-22 Seagen Inc. Antibody masking domains
WO2023049825A1 (en) 2021-09-24 2023-03-30 Seagen Inc. Improved antibody masking domains
WO2023073645A1 (en) 2021-10-29 2023-05-04 Takeda Pharmaceutical Company Limited Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
WO2023108102A1 (en) * 2021-12-10 2023-06-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Anti-lcn-2 antibodies as a treatment for eye disorders
TW202400137A (zh) 2022-03-17 2024-01-01 美商思進公司 喜樹鹼偶聯物
WO2023245106A1 (en) * 2022-06-16 2023-12-21 Abbvie Biotherapeutics Inc. Anti-cd19 antibody drug conjugates
WO2024038115A1 (en) 2022-08-17 2024-02-22 Morphosys Ag Therapy comprising anti-cd19 antibody and ezh2 modulators
WO2024064714A2 (en) 2022-09-21 2024-03-28 Seagen Inc. Antibodies that bind cd228
WO2024097816A1 (en) 2022-11-03 2024-05-10 Seagen Inc. Anti-avb6 antibodies and antibody-drug conjugates and their use in the treatment of cancer
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5686072A (en) * 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5635483A (en) * 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) * 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
ES2233928T3 (es) * 1993-10-01 2005-06-16 Teikoku Hormone Mfg. Co., Ltd. Derivados de dolastatina.
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
NZ507381A (en) * 1998-04-21 2003-12-19 Micromet Ag CD19xCD3 specific polypeptides and uses thereof
AU2001297703B2 (en) * 2000-11-07 2006-10-19 City Of Hope CD19-specific redirected immune cells
WO2002080987A1 (en) * 2001-04-09 2002-10-17 Progenics Pharmaceuticals, Inc. Anti-cd19 immunotoxins
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
BR122019027966B8 (pt) * 2002-05-02 2021-07-27 Wyeth Corp conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos
WO2004010957A2 (en) * 2002-07-31 2004-02-05 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US7662387B2 (en) * 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
ES2322267T3 (es) * 2003-04-09 2009-06-18 Genentech, Inc. Terapia de una enfermedad autoinmunologica en un paciente que presenta una respuesta inadecuada a un inhibidor de tnf-alfa.
AU2004242846A1 (en) * 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
US7109304B2 (en) * 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
US20050048617A1 (en) * 2003-08-18 2005-03-03 Medimmune, Inc. Humanization of antibodies
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
CA2558650A1 (en) * 2004-03-08 2005-09-22 The Johns Hopkins University Device and method for medical training and evaluation
US7691962B2 (en) * 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
CA2580141C (en) * 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
ES2715776T3 (es) 2004-11-12 2019-06-06 Seattle Genetics Inc Auristatinas que tienen una unidad de ácido aminobenzoico en el extremo N
CN1775808A (zh) * 2004-11-15 2006-05-24 中国医学科学院血液学研究所 用于靶向结合淋巴细胞白血病细胞的抗cd19的工程抗体及其用途
CN105535967B (zh) 2005-02-15 2022-05-03 杜克大学 抗cd19抗体及其在肿瘤学中的应用
EP3479844B1 (en) * 2005-04-15 2023-11-22 MacroGenics, Inc. Covalent diabodies and uses thereof
AU2006244445B2 (en) 2005-05-05 2013-04-18 Duke University Anti-CD19 antibody therapy for autoimmune disease
EP1904101A4 (en) * 2005-06-08 2011-06-15 Univ Duke ANTI-CD19 ANTIBODY THERAPY FOR TRANSPLANTATION
CN104926938B (zh) * 2005-06-17 2019-06-04 惠氏有限责任公司 纯化含Fc区蛋白的方法
US8097703B2 (en) 2005-06-20 2012-01-17 Medarex, Inc. CD19 antibodies and their uses
HUE057936T2 (hu) 2005-07-18 2022-06-28 Seagen Inc Béta-glükuronid-linker-hatóanyag konjugátumok
CN101351477B (zh) * 2005-12-30 2011-11-16 默克专利有限公司 具有降低的免疫原性的抗cd19抗体
US20070225595A1 (en) 2006-01-17 2007-09-27 Don Malackowski Hybrid navigation system for tracking the position of body tissue
US20070166306A1 (en) * 2006-01-17 2007-07-19 Fey Georg H M Anti-CD19 antibody composition and method
EP1973947A2 (en) * 2006-01-20 2008-10-01 Welson Pharmaceuticals, Inc. Immunoconjugates with improved efficacy for the treatment of diseases
US20070178103A1 (en) * 2006-01-30 2007-08-02 Fey Georg H CD19-specific immunotoxin and treatment method
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2007103288A2 (en) * 2006-03-02 2007-09-13 Seattle Genetics, Inc. Engineered antibody drug conjugates
PT2059536E (pt) 2006-08-14 2014-04-14 Xencor Inc Anticorpos otimizados que visam cd19
EP2066349B1 (en) * 2006-09-08 2012-03-28 MedImmune, LLC Humanized anti-cd19 antibodies and their use in treatment of tumors, transplantation and autoimmune diseases
ES2523915T5 (es) * 2006-12-01 2022-05-26 Seagen Inc Agentes de unión a la diana variantes y usos de los mismos
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
US7968687B2 (en) 2007-10-19 2011-06-28 Seattle Genetics, Inc. CD19 binding agents and uses thereof
PL2842575T3 (pl) 2008-03-18 2018-02-28 Seattle Genetics, Inc. Koniugaty aurystatyny lek łącznik
CA2723197C (en) 2008-05-02 2017-09-19 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation

Also Published As

Publication number Publication date
DK2211904T3 (en) 2016-10-24
US20180326087A1 (en) 2018-11-15
US8242252B2 (en) 2012-08-14
JP2011500725A (ja) 2011-01-06
AU2008311815A1 (en) 2009-04-23
EP2211904B1 (en) 2016-08-17
ES2599172T3 (es) 2017-01-31
LT2211904T (lt) 2016-11-25
CN101903403B (zh) 2016-03-16
RU2476441C2 (ru) 2013-02-27
US9073993B2 (en) 2015-07-07
AU2008311815B2 (en) 2014-02-06
US20090136526A1 (en) 2009-05-28
HUE031533T2 (hu) 2017-07-28
KR101658083B1 (ko) 2016-09-30
WO2009052431A3 (en) 2010-01-14
US9919061B2 (en) 2018-03-20
HK1143321A1 (zh) 2010-12-31
CY1118349T1 (el) 2017-06-28
EP2211904A4 (en) 2011-10-19
RU2010115886A (ru) 2011-10-27
JP2015129131A (ja) 2015-07-16
US20110312088A1 (en) 2011-12-22
US11331394B2 (en) 2022-05-17
JP5727786B2 (ja) 2015-06-03
US20150283255A1 (en) 2015-10-08
CA2702555A1 (en) 2009-04-23
US20180000961A9 (en) 2018-01-04
US7968687B2 (en) 2011-06-28
KR20100097655A (ko) 2010-09-03
WO2009052431A2 (en) 2009-04-23
PL2211904T3 (pl) 2017-04-28
US20230033859A1 (en) 2023-02-02
US20120294853A1 (en) 2012-11-22
PT2211904T (pt) 2016-11-02
CN101903403A (zh) 2010-12-01
HRP20161345T1 (hr) 2016-11-18
MX2010004219A (es) 2010-08-09
EP2211904A2 (en) 2010-08-04

Similar Documents

Publication Publication Date Title
HK1143321A1 (zh) 的結合劑及其用途
PT2124638T (pt) Composição de aperfeiçoamento de desempenho e utilização da mesma
EP2114900A4 (en) COMPOUNDS ON THIOPYRIMIDINE BASE AND APPLICATIONS THEREOF
GB0701426D0 (en) Compounds and their use
HK1208000A1 (en) Thioninium compounds and their use
GB0611115D0 (en) Compounds and their use
EP2069371A4 (en) ORGANO ARSENOXIDE COMPOUNDS AND THEIR USE
IL202496A0 (en) Compounds and uses thereof 849
EP2133326A4 (en) NEW PSEUDOGLYCOLIPID AND ITS USE
GB0718718D0 (en) Compound and use thereof
IL192820A0 (en) Novel compounds and use thereof
GB0619611D0 (en) Compounds and their use
GB0708445D0 (en) Compounds and uses thereof
GB0625165D0 (en) Novel binding agents and uses thereof
GB0722678D0 (en) Compounds and their use II
IL200459A0 (en) Alpha-halo-and alpha-alkyl-cyclopropylcarboxy compounds and uses thereof
GB0610888D0 (en) Compounds and their use
GB0603374D0 (en) Compounds and their use
GB0619610D0 (en) Compounds and their use
GB0603376D0 (en) Compounds and their use
GB0603378D0 (en) Compounds and their use
GB0608846D0 (en) Compounds and their use
GB0619609D0 (en) Compounds and their use
GB0616577D0 (en) Compounds and their use
GB0625144D0 (en) Novel binding agents